SAMPOST is a national post-doctoral programme that is funded within the framework of the strategy programme “Pharmaceuticals, Biotechnology and Biomedical Engineering – a part of Innovative Sweden”. This strategy programme is the result of a dialogue between the government and industrial organisations such as SwedenBIO and the Swedish Association of the Pharmaceutical Industry, companies such as AstraZeneca, Biovitrum and BioInvent, and representatives of universities, trade unions and R&D funders.
The aim of the SAMPOST programme is to strengthen industrial development and competitiveness in the pharmaceutical, biotechnology and biomedical engineering sectors. This will be achieved by improving opportunities for the mobility and qualification of young, promising researchers who should be able to conduct high-quality, industrially-relevant research in co-operation with the industry. The programme will increase corporate access to new knowledge at the universities and improve the potential for both industry and the universities to convert results into innovation and growth.
A budget of SEK 35 million has been allocated to the SAMPOST programme for the period 2006-2010. The total budget for the programme, however, is at least SEK 70 million, as the participating companies must contribute at least the same amount.
In total, two calls for proposals have been made under the programme.